myTomorrows collaborates with the ALS Association to give easy access to clinical trials for patients

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags ALS neurodegenerative diseases Clinical trial Patient centricity

In a significant move aimed at supporting patients battling amyotrophic lateral sclerosis (ALS), myTomorrows has announced a strategic partnership with the ALS Association, a leading nonprofit organization dedicated to combating ALS.

myTomorrows is a global health technology company and says it is revolutionizing the landscape of clinical trial accessibility through its original platform. The partnership with the ALS Association underscores myTomorrows' commitment to ensuring that individuals facing life-threatening diseases have access to all potential treatment options.

Under this collaboration, myTomorrows says the ALS Association will make the most of its extensive database of ongoing clinical trials and use its patient navigation service. This initiative, the collaborators say, aims to empower treating physicians and ALS patients with comprehensive information about pre-approval treatment options and guide them towards relevant clinical trials.

ALS, a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, currently has no cure. With symptoms including loss of movement, speech impairment, and eventually respiratory failure, ALS poses significant challenges for patients and their families. The partnership between the ALS Association and myTomorrows seeks to alleviate some of these challenges by facilitating access to clinical trials.

Both say that while numerous clinical trials are underway to evaluate potential ALS treatments, patient recruitment remains a major hurdle for pharmaceutical companies. myTomorrows' platform addresses this issue by bridging the gap between pharmaceutical companies, physicians, and patients, streamlining the enrollment process, and expediting the development of potential therapies.

Michel van Harten, CEO of myTomorrows, is optimistic about the partnership's potential impact. He said: “ALS is a devastating disease with substantial unmet needs. By collaborating with esteemed patient advocacy groups like the ALS Association, we can empower a larger cohort of ALS patients and their physicians to explore clinical trial opportunities, thereby overcoming barriers to accessing treatment options.”

Pam Knott, vice president of data and technology at the ALS Association, highlighted the importance of research participation in advancing ALS treatment, saying, “we are thrilled about this partnership as it presents an opportunity to expedite enrollment of ALS patients into clinical trials, ultimately driving progress towards finding effective treatments and improving patient outcomes.”

Through this collaboration, myTomorrows and the ALS Association say they aim to enhance the clinical trial experience for ALS patients and accelerate the development of potential therapies for this debilitating disease.

The Association is the largest philanthropic funder of ALS research in the world, supporting projects around the world and says it has the highest potential impact for people living with ALS and their caregivers. Since the ice bucket challenge in 2014, it has been committed more than $154 million to support more than 550 projects in the US and 18 other countries, with the goal of making ALS a livable disease for everyone, everywhere, until it can be cured.  

Related news

Follow us


View more